Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on inhibiting ...

British Association of Dermatologists Biologic Interventions Register (BADBIR) found prior serious infections may outweigh ...

While a health care provider like a dermatologist can diagnose you with psoriasis based on a skin exam and medical history, ...

European Commission approves Bristol Myers Squibb’s Sotyktu for the treatment of active psoriatic arthritis in adults: Princeton, New Jersey Monday, May 11, 2026, 15:00 Hrs [IST ...

Tildrakizumab maintained efficacy and safety in obese patients with scalp psoriasis over 52 weeks. Find out more about the ...

USA: A new study has highlighted promising results for a targeted therapy in managing generalized pustular psoriasis (GPP), a ...

A real-world study found tildrakizumab improved skin clearance, symptoms, and quality of life in adults with plaque psoriasis ...

Researchers have found in a new study that the success rates of root canal treatment (RCT) in patients with autoimmune ...

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 ...

Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and ...

The stern warning says using the affected product could produce infections with possible "severe or life-threatening adverse ...